A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery
Completed
OMRIX Biopharmaceuticals
Phase 3
2004-11-01
The purpose of this study is to see if Human Thrombin is as effective as Bovine Thrombin in
stopping surgical bleeding within 10 minutes of application.
A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery
Completed
Ethicon, Inc.
Phase 3
2004-11-01
The purpose of this study is to see if Human Thrombin is as effective as Bovine Thrombin in
stopping surgical bleeding within 10 minutes of application.
Study of Recombinant Human Thrombin for Bleeding During Surgery
Completed
ZymoGenetics
Phase 3
2005-10-01
The purpose of this study is to determine whether recombinant human Thrombin (rhThrombin) is
effective in stopping bleeding during surgery, in comparison with bovine thrombin.
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
Completed
Children's Medical Center Dallas
Phase 1/Phase 2
2008-03-01
The purpose of this study is to determine whether control of inflammatory pathways mediated
by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in
expression of genes that are otherwise overexpressed as a consequence of IL-1 beta effects in
children with newly diagnosed type 1 diabetes. Ultimately, we believe that control of IL-1
beta pathways will be associated with preserved insulin secretory capacity.
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
Completed
University of Texas Southwestern Medical Center
Phase 1/Phase 2
2008-03-01
The purpose of this study is to determine whether control of inflammatory pathways mediated
by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in
expression of genes that are otherwise overexpressed as a consequence of IL-1 beta effects in
children with newly diagnosed type 1 diabetes. Ultimately, we believe that control of IL-1
beta pathways will be associated with preserved insulin secretory capacity.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.